As winter arrives, the stark shift to dry air and central heating presents a challenge for those with eczema and psoriasis.

The global psoriasis burden shows a slight increase from 1990 to 2021 and is projected to rise further by 2050.

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

GLP-1 agonists appeared to have a bigger impact on the physical and mental health of patients with psoriasis compared with other patients, a large retrospective cohort study showed. Reductions in ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, a new study says. Psoriasis patients taking GLP-1 drugs had a 78% lower risk of ...

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...

Psoriasis is a chronic autoimmune skin condition causing red, scaly patches. It can appear on various body parts, including the scalp, elbows, knees, hands, feet, lower back, torso, face, and ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

Dupilumab treatment in atopic dermatitis patients shows a 58% higher risk of developing psoriasis compared to other systemic treatments. The number needed to harm is 94, indicating a limited absolute ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Roflumilast foam 0.3% is a formulation that can treat ...

A recent Phase 3 clinical trial demonstrated that a steroid-free topical foam, roflumilast (Zoryve), significantly improved the signs and symptoms of psoriasis on both the scalp and body. The foam ...